TORONTO, Feb. 4, 2026 /CNW/ – Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for Pr AJOVY® (fremanezumab solution for subcutaneous injection) ...
Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and ...
The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...
Treatment with fremanezumab led to a significantly greater reduction in monthly migraine days and monthly headache days. The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) ...
Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this debilitating condition. Teva Pharmaceuticals announced that the FDA has approved Ajovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results